Global genomics in cancer care market is expected to
reach USD 9.22 billion by 2022, according to a new report by Grand View
Research, Inc. Increasing prevalence of cancer coupled with adoption of next
generation sequencing for the diagnosis & treatment is expected to fuel the
market with future growth opportunities. Increasing incidences of cancer
triggers the demand for cost effective and accurate diagnostics in coming
years.
In addition, increasing demand for
personalized medicines in molecular characterization of cancer to identify
therapeutic targets is the factor attributing towards the market growth.
Similarly, factors such as cost reduction in genome sequencing, growing
healthcare expenditure levels and development of effective diagnostics &
therapeutic procedures for cancer are responsible for the potential growth of
genomics in cancer care.
Browse full research report on Genomics
In Cancer Care Market:
https://www.grandviewresearch.com/industry-analysis/genomics-in-cancer-care-market
Further key
findings from the study suggest:
- Instrument segment dominated the overall
market in terms of revenue share as of 2014 and accounted for 33.4% of
market owing to high cost associated with it. Whereas, consumables are
most widely used product segment in genome testing as they are
indispensible component and frequently required to perform the test.
- Demand for services such as next generation
sequencing, PCR and other such as cancer risk management & genetic
testing are expected to grow over the forecast period due to increasing
outsourcing activities to perform genome analysis. High cost of performing
genetic tests and growing awareness pertaining to associated benefits with
the use of these technologies are high impact rendering drivers for this
segment.
- Drug discovery and development segment is
expected to show lucrative CAGR of 17.6% during the forecast period owing
to increasing demand for effective treatment for cancer and growing
investment in biomedicines by manufacturers for the development of novel
products.
- Genome sequencing held the dominant share of
technology segment as it is most prominently used for diagnosis due to
associate benefits such as faster and accurate method. It is expected to
show significant growth rate of 17.5% in coming years owing to remarkable
decrease in the cost for genome sequencing and increasing adoption rates.
- The cancer research segment held the largest
share of 34.1% in 2014 due to increasing demand for faster & accurate
diagnostic methods to treat variety of cancer. Other use such as
commercial adoption of genetic testing is expected to be fastest growing
segment owing to increasing demand of cancer genomic testing to fulfill
unmet needs in healthcare sector.
- Some key players operating in this market
include Beckman Coulter Inc., Illumina, Inc, Affymetrix, Roche
Diagnostics, Agilent Technologies, Cancer Genetics Inc., Danaher
Corporation, Bio-Rad Labs, Pacific Biosciences, Quest Diagnostics, Sigma
Aldrich, Luminex, Thermo Fisher scientific, Oxford Gene Technology.,
PerkinElmer, Qiagen, and GE Healthcare.
Browse request sample of this report by
Grand View Research: https://www.grandviewresearch.com/industry-analysis/genomics-in-cancer-care-market/request/rs1
Grand
View Research has segmented the global genomics in cancer care market on the
basis of application and region:
Global genomics
in cancer care product outlook (Revenue, USD Million, 2012 - 2022)
- Instruments
- Consumables
- Services
Global genomics
in cancer care application (Revenue, USD Million, 2012 - 2022)
- Diagnostics
- Personalized
medicine
- Drug discovery &
development
- Research
Global Genomics
in cancer care technology Outlook (Revenue, USD Million, 2012 - 2022)
- Genome sequencing
- PCR
- Microarrays
- Nucleic acid
extraction & purification
- Other
Genomics in
cancer care regional outlook (Revenue, USD Million, 2012 - 2022)
- North America
- U.S
- Canada
- Europe
- U.K
- Germany
- Asia Pacific
- Japan
- China
- India
- Latin America
- Mexico
- Brazil
- MEA
- South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment